secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevance Health, Inc. (ELV)
CIK:        0001156039
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001156039-26-000019
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed
--------------------------------------------------------------------------------

- Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.
- CFO Mark Kaye expands role to oversee Carelon operations including pharmacy, behavioral, value-based care, and care delivery.
- Felicia Norwood consolidates Commercial and Government Health Benefits under a single accountable structure.
- FY2026 adjusted EPS guidance reaffirmed at least $25.50; reported EPS at least $22.30 (incl. $3.20 net unfavorable items).
- Benefit expense ratio guidance reaffirmed at 90.2% +/- 50 bps for full year 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1156039/000115603926000019/0001156039-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1156039/000115603926000019/elv-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001156039-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer